Glenda E Gray1, Zoe Moodie2, Barbara Metch2, Peter B Gilbert2, Linda-Gail Bekker3, Gavin Churchyard4, Maphoshane Nchabeleng5, Koleka Mlisana6, Fatima Laher7, Surita Roux3, Kathryn Mngadi6, Craig Innes4, Matsontso Mathebula5, Mary Allen8, M Julie McElrath2, Michael Robertson9, James Kublin2, Lawrence Corey2. 1. Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa; South African Medical Research Council, Cape Town, South Africa. Electronic address: gray@pixie.co.za. 2. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA. 3. Desmond Tutu HIV Foundation, University of Cape Town, Cape Town, South Africa. 4. Aurum Institute for Health Research, Johannesburg, South Africa. 5. MEDUNSA HIV Clinical Research Unit, University of Limpopo, Mankweng-E, South Africa. 6. Centre for AIDS Programme for Research in South Africa, University of KwaZulu-Natal, Durban, South Africa. 7. Perinatal HIV Research Unit, University of the Witwatersrand, Johannesburg, South Africa. 8. Vaccine Research Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA. 9. Infectious Diseases and Vaccines Clinical Research, Merck and Company, North Wales, PA, USA.
Abstract
BACKGROUND: The HVTN 503/Phambili study, which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa, was stopped when futility criteria in the Step study (assessing the same vaccine in the Americas, Caribbean, and Australia) were met. Here we report long-term follow-up data. METHODS: HVTN 503/Phambili was a double-blind, placebo-controlled, randomised trial that recruited HIV-1 uninfected, sexually active adults aged 18-35 years from five sites in South Africa. Eligible participants were randomly assigned (1:1) by computer-generated random numbers to either vaccine or placebo, stratified by site and sex. Cox proportional hazards models were used to estimate HIV-1 infection in the modified intention-to-treat cohort, all of whom were unmasked early in follow-up. The trial is registered with ClinicalTrials.gov, number NCT00413725 and the South African National Health Research Database, number DOH-27-0207-1539. FINDINGS:Between Jan 24, 2007, and Sept 19, 2007, 801 participants (26·7%) of a planned 3000 were randomly assigned (400 tovaccine, 401 to placebo); 216 (27%) received only one injection, 529 (66%) received only two injections, and 56 (7%) received three injections. At a median follow-up of 42 months (IQR 31-42), 63 vaccine recipients (16%) had HIV-1 infection compared with 37 placebo recipients (9%; adjusted HR 1·70, 95% CI 1·13-2·55; p=0·01). Risk for HIV-1 infection did not differ according to the number of vaccinations received, sex, circumcision, or adenovirus type 5 (Ad5) serostatus. Differences in risk behaviour at baseline or during the study, or annualised dropout rate (7·7% [95% CI 6·2-9·5] for vaccine recipients vs 8·8% [7·1-10·7] for placebo recipients; p=0·40) are unlikely explanations for the increased rate of HIV-1 infections seen in vaccine recipients. INTERPRETATION: The increased risk of HIV-1 acquisition in vaccine recipients, irrespective of number of doses received, warrants further investigation to understand the biological mechanism. We caution against further use of the Ad5 vector for HIV vaccines. FUNDING: National Institute of Allergy and Infectious Diseases, Merck, and South African Medical Research Council.
RCT Entities:
BACKGROUND: The HVTN 503/Phambili study, which assessed the efficacy of the Merck Ad5 gag/pol/nef subtype B HIV-1 preventive vaccine in South Africa, was stopped when futility criteria in the Step study (assessing the same vaccine in the Americas, Caribbean, and Australia) were met. Here we report long-term follow-up data. METHODS: HVTN 503/Phambili was a double-blind, placebo-controlled, randomised trial that recruited HIV-1 uninfected, sexually active adults aged 18-35 years from five sites in South Africa. Eligible participants were randomly assigned (1:1) by computer-generated random numbers to either vaccine or placebo, stratified by site and sex. Cox proportional hazards models were used to estimate HIV-1 infection in the modified intention-to-treat cohort, all of whom were unmasked early in follow-up. The trial is registered with ClinicalTrials.gov, number NCT00413725 and the South African National Health Research Database, number DOH-27-0207-1539. FINDINGS: Between Jan 24, 2007, and Sept 19, 2007, 801 participants (26·7%) of a planned 3000 were randomly assigned (400 to vaccine, 401 to placebo); 216 (27%) received only one injection, 529 (66%) received only two injections, and 56 (7%) received three injections. At a median follow-up of 42 months (IQR 31-42), 63 vaccine recipients (16%) had HIV-1 infection compared with 37 placebo recipients (9%; adjusted HR 1·70, 95% CI 1·13-2·55; p=0·01). Risk for HIV-1 infection did not differ according to the number of vaccinations received, sex, circumcision, or adenovirus type 5 (Ad5) serostatus. Differences in risk behaviour at baseline or during the study, or annualised dropout rate (7·7% [95% CI 6·2-9·5] for vaccine recipients vs 8·8% [7·1-10·7] for placebo recipients; p=0·40) are unlikely explanations for the increased rate of HIV-1 infections seen in vaccine recipients. INTERPRETATION: The increased risk of HIV-1 acquisition in vaccine recipients, irrespective of number of doses received, warrants further investigation to understand the biological mechanism. We caution against further use of the Ad5 vector for HIV vaccines. FUNDING: National Institute of Allergy and Infectious Diseases, Merck, and South African Medical Research Council.
Authors: Craig R Cohen; Anna-Barbara Moscicki; Mark E Scott; Yifei Ma; Stephen Shiboski; Elizabeth Bukusi; Ibrahim Daud; Anu Rebbapragada; Joelle Brown; Rupert Kaul Journal: AIDS Date: 2010-08-24 Impact factor: 4.177
Authors: Scott M Hammer; Magdalena E Sobieszczyk; Holly Janes; Shelly T Karuna; Mark J Mulligan; Doug Grove; Beryl A Koblin; Susan P Buchbinder; Michael C Keefer; Georgia D Tomaras; Nicole Frahm; John Hural; Chuka Anude; Barney S Graham; Mary E Enama; Elizabeth Adams; Edwin DeJesus; Richard M Novak; Ian Frank; Carter Bentley; Shelly Ramirez; Rong Fu; Richard A Koup; John R Mascola; Gary J Nabel; David C Montefiori; James Kublin; M Juliana McElrath; Lawrence Corey; Peter B Gilbert Journal: N Engl J Med Date: 2013-10-07 Impact factor: 91.245
Authors: G E Gray; B Metch; G Churchyard; K Mlisana; M Nchabeleng; M Allen; Z Moodie; J Kublin; L-G Bekker Journal: Vaccine Date: 2013-01-29 Impact factor: 3.641
Authors: Danilo R Casimiro; Ling Chen; Tong-Ming Fu; Robert K Evans; Michael J Caulfield; Mary-Ellen Davies; Aimin Tang; Minchun Chen; Lingyi Huang; Virginia Harris; Daniel C Freed; Keith A Wilson; Sheri Dubey; De-Min Zhu; Denise Nawrocki; Henryk Mach; Robert Troutman; Lynne Isopi; Donna Williams; William Hurni; Zheng Xu; Jeffrey G Smith; Su Wang; Xu Liu; Liming Guan; Romnie Long; Wendy Trigona; Gwendolyn J Heidecker; Helen C Perry; Natasha Persaud; Timothy J Toner; Qin Su; Xiaoping Liang; Rima Youil; Michael Chastain; Andrew J Bett; David B Volkin; Emilio A Emini; John W Shiver Journal: J Virol Date: 2003-06 Impact factor: 5.103
Authors: Walter Jaoko; Etienne Karita; Kayitesi Kayitenkore; Gloria Omosa-Manyonyi; Susan Allen; Soe Than; Elizabeth M Adams; Barney S Graham; Richard A Koup; Robert T Bailer; Carol Smith; Len Dally; Bashir Farah; Omu Anzala; Claude M Muvunyi; Jean Bizimana; Tony Tarragona-Fiol; Philip J Bergin; Peter Hayes; Martin Ho; Kelley Loughran; Wendy Komaroff; Gwynneth Stevens; Helen Thomson; Mark J Boaz; Josephine H Cox; Claudia Schmidt; Jill Gilmour; Gary J Nabel; Patricia Fast; Job Bwayo Journal: PLoS One Date: 2010-09-21 Impact factor: 3.240
Authors: Catia T Perciani; Bashir Farah; Rupert Kaul; Mario A Ostrowski; Salaheddin M Mahmud; Omu Anzala; Walter Jaoko; Kelly S MacDonald Journal: J Clin Invest Date: 2019-01-22 Impact factor: 14.808
Authors: Stephen R Walsh; Zoe Moodie; Andrew J Fiore-Gartland; Cecilia Morgan; Marissa B Wilck; Scott M Hammer; Susan P Buchbinder; Spyros A Kalams; Paul A Goepfert; Mark J Mulligan; Michael C Keefer; Lindsey R Baden; Edith M Swann; Shannon Grant; Hasan Ahmed; Fusheng Li; Tomer Hertz; Steven G Self; David Friedrich; Nicole Frahm; Hua-Xin Liao; David C Montefiori; Georgia D Tomaras; M Juliana McElrath; John Hural; Barney S Graham; Xia Jin Journal: J Infect Dis Date: 2015-10-15 Impact factor: 5.226